Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies

Revista Española de Quimioterapia, Journal Year: 2023, Volume and Issue: 36(4), P. 380 - 391

Published: April 24, 2023

Recipients of solid organ transplants (SOT) are at higher risk infection by SARS-CoV-2 virus especially due to chronic immunosuppression therapy and frequent multiple comorbid conditions. COVID-19 is a potentially life-threatening disease in SOT recipients, with an increased likelihood progressing severe disease, the need hospitalization, admission intensive care unit (ICU) mechanical ventilatory support. This article presents updated review different aspects related outcome recipients. In nvaccinated associated high mortality rate, in-patient ICU admission, impaired graft function or rejection disease. vaccinated recipients even after full vaccination, there reduction mortality, but course may continue be severe, influenced time from transplant, net state having suffered dysfunction. develop lower immunity mRNA vaccines suboptimal response. Treatment mAbs provides favorable outcomes non-hospitalized for rates emergency department visits, care, progression death. However, broad vaccination therapeutic options required, particularly light tendency adapt evade both natural vaccine-induced immunity.

Language: Английский

None

Revista Española de Quimioterapia, Journal Year: 2023, Volume and Issue: 36(4)

Published: May 3, 2023

Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in population aged 65 or over ABSTRACTMost complications deaths related to seasonal flu occur elderly (≥65 years) with comorbidities, is most effective way prevent them.Immunization less older adults due immunosenescence.MF59-adjuvanted vaccines, designed improve magnitude, persistence amplitude immune response people, have been used clinical practice since 1997 their trivalent formulation and, 2020, tetravalent formulation.Data from various studies show that these vaccines are not only safe for all age groups, a reactogenicity profile similar conventional vaccine, but also they especially boosting by increasing antibody titers after vaccination significantly reducing risk hospital admission.Adjuvanted shown provide cross-protection against heterologous strains be as high-dose over.In this review, scientific evidence on efficacy MF59-adjuvanted real people ≥65 years analyzed through narrative descriptive review literature data trials, observational systematic reviews meta-analysis.

Language: Английский

Impact of the COVID-19 pandemic on ovarian tissue cryopreservation planning in the Bologna clinical center

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Dec. 15, 2022

Treatment of patients with COVID-19 has been a priority by competing the treatment any other disease due to limited hospital resources. The current pandemic situation focused attention healthcare providers around world away from all non-emergency health problems, including oncofertility. aim study was evaluate repercussions on activity levels ovarian tissue cryopreservation (OTC) in our center.The analyzed number treated for OTC center during three periods: pre-pandemic period: March 2019-February 2020, 2020-February 2021 and post-pandemic 2021-February 2022.In routine operation completely reorganized, allowing only urgent interventions. Continuing urgently preserve fertility required rapid changes standard practices care these vulnerable patients. Despite modifications, there no difference performed among periods analyzed. Similarly, who did not perform same over years analyzed.Despite local national restructuring conserve resources protect community, it is significant continue offering fertility-sparing cancer This emphasis importance preserving despite further highlights essential nature this procedure.

Language: Английский